IL273516B2 - Methods of isolating t cells having antigenic specificity for a p53 cancer-specific mutation - Google Patents

Methods of isolating t cells having antigenic specificity for a p53 cancer-specific mutation

Info

Publication number
IL273516B2
IL273516B2 IL273516A IL27351620A IL273516B2 IL 273516 B2 IL273516 B2 IL 273516B2 IL 273516 A IL273516 A IL 273516A IL 27351620 A IL27351620 A IL 27351620A IL 273516 B2 IL273516 B2 IL 273516B2
Authority
IL
Israel
Prior art keywords
cells
acid sequence
cancer
amino acid
mutated human
Prior art date
Application number
IL273516A
Other languages
English (en)
Hebrew (he)
Other versions
IL273516A (en
IL273516B1 (en
Original Assignee
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Health filed Critical Us Health
Publication of IL273516A publication Critical patent/IL273516A/en
Publication of IL273516B1 publication Critical patent/IL273516B1/en
Publication of IL273516B2 publication Critical patent/IL273516B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4238—Regulators of development
    • A61K40/424—Apoptosis related proteins, e.g. survivin or livin
    • A61K40/4241—Apoptosis related proteins, e.g. survivin or livin p53
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4746—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used p53
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/1121—Dendritic cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL273516A 2017-09-29 2018-09-17 Methods of isolating t cells having antigenic specificity for a p53 cancer-specific mutation IL273516B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762565464P 2017-09-29 2017-09-29
PCT/US2018/051280 WO2019067242A1 (en) 2017-09-29 2018-09-17 METHODS FOR ISOLATING T CELLS HAVING ANTIGENIC SPECIFICITY FOR SPECIFIC MUTATION OF CANCER P53

Publications (3)

Publication Number Publication Date
IL273516A IL273516A (en) 2020-05-31
IL273516B1 IL273516B1 (en) 2025-02-01
IL273516B2 true IL273516B2 (en) 2025-06-01

Family

ID=63763012

Family Applications (1)

Application Number Title Priority Date Filing Date
IL273516A IL273516B2 (en) 2017-09-29 2018-09-17 Methods of isolating t cells having antigenic specificity for a p53 cancer-specific mutation

Country Status (10)

Country Link
US (1) US20200316121A1 (enExample)
EP (2) EP3688142B1 (enExample)
JP (1) JP7391015B2 (enExample)
KR (1) KR102809909B1 (enExample)
CN (1) CN111344394A (enExample)
AU (1) AU2018342245B2 (enExample)
CA (1) CA3080274A1 (enExample)
IL (1) IL273516B2 (enExample)
SG (1) SG11202002635RA (enExample)
WO (1) WO2019067242A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS62865B1 (sr) 2016-12-08 2022-02-28 Immatics Biotechnologies Gmbh Novi t-ćelijski receptori i imunoterapija u kojoj se koriste
DE102016123847B3 (de) * 2016-12-08 2018-04-05 Immatics Biotechnologies Gmbh Neue T-Zellrezeptoren und deren Verwendung in Immuntherapie
GB201700621D0 (en) 2017-01-13 2017-03-01 Guest Ryan Dominic Method,device and kit for the aseptic isolation,enrichment and stabilsation of cells from mammalian solid tissue
AU2018269370B2 (en) 2017-05-16 2025-06-05 The Johns Hopkins University Manabodies and methods of using
WO2020264269A1 (en) * 2019-06-27 2020-12-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors recognizing r175h or y220c mutation in p53
CN112390875B (zh) * 2019-08-16 2023-01-24 香雪生命科学技术（广东）有限公司 一种识别afp的高亲和力t细胞受体
WO2021127184A1 (en) * 2019-12-17 2021-06-24 The Johns Hopkins University MANAbodies TARGETING TUMOR ANTIGENS AND METHODS OF USING
KR20220119439A (ko) 2019-12-20 2022-08-29 인스틸 바이오 유케이 리미티드 종양 침윤 림프구를 분리하기 위한 장치 및 방법 및 그것의 용도
CN113621070A (zh) 2020-05-06 2021-11-09 华夏英泰（北京）生物技术有限公司 一种t细胞抗原受体、其多聚体复合物及其制备方法和应用
CN116472050A (zh) * 2020-09-04 2023-07-21 美国卫生和人力服务部 识别p53中r273c或y220c突变的t细胞受体
CN112301088B (zh) * 2020-10-21 2022-12-13 杭州纽安津生物科技有限公司 一种筛选新生抗原或新生抗原编码序列的方法
IL305393A (en) 2021-02-25 2023-10-01 Alaunos Therapeutics Inc Recombinant vectors comprising polycistronic expression cassettes and methods of use thereof
US20240165120A1 (en) * 2021-03-08 2024-05-23 Taiho Pharmaceutical Co., Ltd. Treating cancer in patient having co-occurring genetic alteration in fgfr2 and a cancer driver gene
WO2022212682A2 (en) * 2021-03-31 2022-10-06 The Johns Hopkins University Methods and materials for targeting tumor antigens
CN117957245A (zh) * 2021-05-07 2024-04-30 美国政府(由卫生和人类服务部的部长所代表) 识别p53中的c135y、r175h或m237i突变的t细胞受体
AU2022310862A1 (en) 2021-07-14 2024-02-01 Regeneron Pharmaceuticals, Inc. Engineered t cell receptors fused to binding domains from antibodies
US20240415886A1 (en) * 2021-10-29 2024-12-19 Yafei Hou T cell receptor recognizing r175h mutation in p53 and its application
IL316032A (en) 2022-04-08 2024-11-01 Regeneron Pharma Multicomponent receptor and signaling complexes
WO2024131372A1 (zh) * 2022-12-23 2024-06-27 上海市第一人民医院 靶向巨细胞病毒pp65的TCR和表达其的T细胞及应用
WO2024243542A1 (en) * 2023-05-25 2024-11-28 Elicio Therapeutics, Inc. Compositions containing p53 peptide amphiphiles and methods of use thereof
WO2025060149A1 (zh) * 2023-09-22 2025-03-27 上海市第一人民医院 一种分离的tcr及其用途
CN116970058B (zh) * 2023-09-22 2023-12-15 成都朗谷生物科技股份有限公司 针对tp53基因r249s突变的肿瘤新抗原多肽及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2139012T3 (es) * 1992-05-26 2000-02-01 Univ Leiden Peptidos de la proteina p53 humana destinados para ser utilizados en composiciones que inducen una reaccion en los linfocitos t humanos, y linfocitos t citotoxicos especificos de la proteina p53 humana.
JPH0959175A (ja) * 1995-06-12 1997-03-04 Meiji Milk Prod Co Ltd 抗腫瘍免疫活性化剤
US8034334B2 (en) 2002-09-06 2011-10-11 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Immunotherapy with in vitro-selected antigen-specific lymphocytes after non-myeloablative lymphodepleting chemotherapy
GB2440736A (en) * 2006-08-10 2008-02-13 Medical Res Council Crystals of mutant p53 polypeptidtes
US8383099B2 (en) 2009-08-28 2013-02-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adoptive cell therapy with young T cells
US20120244133A1 (en) 2011-03-22 2012-09-27 The United States of America, as represented by the Secretary, Department of Health and Methods of growing tumor infiltrating lymphocytes in gas-permeable containers
US10973894B2 (en) 2014-10-02 2021-04-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Methods of isolating T cells having antigenic specificity for a cancer-specific mutation
CN107074932A (zh) 2014-10-02 2017-08-18 美国卫生和人力服务部 分离对癌症特异性突变具有抗原特异性的t细胞受体的方法
KR20170075785A (ko) * 2014-11-05 2017-07-03 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 유전자 변형된 면역 효과기 세포 및 면역 효과기 세포의 증식용 가공된 세포
ES2784261T3 (es) * 2014-11-26 2020-09-23 Us Health Receptores de células T anti-KRAS mutado
MA50651A (fr) * 2017-09-29 2020-08-05 Us Health Récepteurs de lymphocytes t reconnaissant p53 mutée

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
INGE MARIE SVANE ET AL,, VACCINATION WITH P53 PEPTIDE-PULSED DENDRITIC CELLS IS ASSOCIATED WITH DISEASE STABILIZATION IN PATIENTS WITH P53 EXPRESSING ADVANCED BREAST CANCER; MONITORING OF SERUM YKL-40 AND IL-6 AS RESPONSE BIOMARKERS, 7 February 2007 (2007-02-07) *
KATERINA SHAMALOV ET AL,, THE MUTATIONAL STATUS OF P53 CAN INFLUENCE ITS RECOGNITION BY HUMAN T-CELLS, 31 January 2017 (2017-01-31) *

Also Published As

Publication number Publication date
IL273516A (en) 2020-05-31
EP3688142B1 (en) 2025-04-09
US20200316121A1 (en) 2020-10-08
CA3080274A1 (en) 2019-04-04
CN111344394A (zh) 2020-06-26
AU2018342245A1 (en) 2020-04-16
EP4495133A2 (en) 2025-01-22
EP4495133A3 (en) 2025-04-09
WO2019067242A1 (en) 2019-04-04
JP2020534839A (ja) 2020-12-03
KR20200065026A (ko) 2020-06-08
KR102809909B1 (ko) 2025-05-22
SG11202002635RA (en) 2020-04-29
JP7391015B2 (ja) 2023-12-04
IL273516B1 (en) 2025-02-01
EP3688142A1 (en) 2020-08-05
AU2018342245B2 (en) 2024-06-13

Similar Documents

Publication Publication Date Title
IL273516B1 (en) Methods for isolating T cells with antigenic specificity for a cancer-specific P53 mutation
JP2020534839A5 (enExample)
JP2017531640A5 (enExample)
Baecher-Allan et al. Regulatory cells and human cancer
Rezaiemanesh et al. Immune cells involved in the pathogenesis of ankylosing spondylitis
Freud et al. NKp80 defines a critical step during human natural killer cell development
Lee et al. T-cell biology in aging, with a focus on lung disease
RU2019128544A (ru) Линии стимулирующих клеток для ex vivo размножения и активации клеток-натуральных киллеров
Martin et al. Controversies on the role of Th17 in cancer: a TGF-β-dependent immunosuppressive activity?
US12252545B2 (en) Therapeutic cell compositions and methods of manufacturing and use thereof
CN104087592B (zh) Afp158-166特异性tcr基因及其转基因t细胞及体外增殖方法及用途
JP2019176869A5 (enExample)
JP2016509839A5 (enExample)
JP2016509840A5 (enExample)
JP2016524914A5 (enExample)
JP2011188872A5 (enExample)
JP2022541523A5 (enExample)
Kayser et al. Rapid generation of NY-ESO-1-specific CD4+ THELPER1 cells for adoptive T-cell therapy
Harfuddin et al. CD137L-stimulated dendritic cells are more potent than conventional dendritic cells at eliciting cytotoxic T-cell responses
Shao et al. Artificial antigen-presenting cells are superior to dendritic cells at inducing antigen-specific cytotoxic T lymphocytes
Xiao et al. Engineered T cells stimulate dendritic cell recruitment and antigen spreading for potent anti-tumor immunity
Michiels et al. Induction of antigen-specific CD8+ cytotoxic T cells by dendritic cells co-electroporated with a dsRNA analogue and tumor antigen mRNA
Wolf et al. Regulatory perspective on in vitro potency assays for human dendritic cells used in anti-tumor immunotherapy
Kalantari et al. Generation of large numbers of highly purified dendritic cells from bone marrow progenitor cells after co-culture with syngeneic murine splenocytes
JP2021521828A5 (enExample)